Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
AIM: The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in ...
Background A 71-year-old woman presented with severe chest pain after an episode of acute emotional distress. Her serum levels of cardiac enzymes were slightly elevated and electrocardiography ...
Acute coronary syndromes are sudden episodes of reduced or no blood flow and therefore oxygen delivery to part of the heart, usually as a result of narrowing or blockage of an artery. The lack of ...
AHA scientific statement provides a framework for standardizing baseline and provocative invasive hemodynamic protocols in HF ...
BACKGROUND: The American Heart Association annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results